Almirall and Forest Laboratories have announced that Phase 3 studies of inhaled aclidinium and Phase 2b studies of an inhaled aclidinium/formoterol combination both met their primary endpoints. As a result, the companies expect to submit regulatory applications for an aclidinium DPI for the treatment of COPD in the US and Europe in mid-2011 and will begin Phase 3 trials for the combination later in the year. Forest has licensed US rights to the product; Almirall retains the rights in the rest of the world. Read the company’s press release.
